Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report.
de Jager VD, van Kempen LC, Cajiao Garcia BN, Hiltermann TJN, van der Wekken AJ, Schuuring E, Willems SM. de Jager VD, et al. Among authors: van der wekken aj. JTO Clin Res Rep. 2024 Oct 17;5(12):100745. doi: 10.1016/j.jtocrr.2024.100745. eCollection 2024 Dec. JTO Clin Res Rep. 2024. PMID: 39735888 Free PMC article.
Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC.
Heersche N, Lanser DAC, Muntinghe-Wagenaar MB, Mohmaed Ali MI, Ulas EB, Trooster TMA, de Jonge E, Oomen-de Hoop E, Paats MS, Bahce I, Croes S, Hendriks LEL, van der Wekken AJ, Dingemans AC, Huitema ADR, van Schaik RHN, Mathijssen RHJ, Veerman GDM. Heersche N, et al. Among authors: van der wekken aj. J Thorac Oncol. 2024 Nov 29:S1556-0864(24)02488-2. doi: 10.1016/j.jtho.2024.11.025. Online ahead of print. J Thorac Oncol. 2024. PMID: 39617342 Free article.
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.
de Jager VD, Plomp P, Paats MS, van Helvert S, Elst AT, van den Berg A, Dubbink HJ, van Geffen WH, Zhang L, Hendriks LEL, Hiltermann TJN, Hiddinga BI, Hijmering-Kappelle LBM, Jalving M, Kluiver J, Koopman B, van Kruchten M, van der Logt EMJ, Piet B, van Putten J, Reitsma BH, Rutgers SR, de Vries M, Stigt JA, Groves MR, Timens W, Willems SM, van Kempen LC, Schuuring E, van der Wekken AJ. de Jager VD, et al. Among authors: van der wekken aj. ESMO Open. 2024 Nov;9(11):103966. doi: 10.1016/j.esmoop.2024.103966. Epub 2024 Nov 4. ESMO Open. 2024. PMID: 39500140 Free PMC article.
An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab.
Kicken MP, Deenen MJ, Moes DJAR, Hendrikx JJMA, van den Borne BEEM, Dumoulin DW, van der Wekken AJ, van den Heuvel MM, Ter Heine R. Kicken MP, et al. Among authors: van der wekken aj. Target Oncol. 2024 Sep;19(5):779-787. doi: 10.1007/s11523-024-01087-4. Epub 2024 Jul 31. Target Oncol. 2024. PMID: 39085452 Free PMC article.
Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer.
Kievit H, Muntinghe-Wagenaar MB, Abdulahad WH, Rutgers A, Hijmering-Kappelle LBM, Hiddinga BI, Ubbels JF, Wijsman R, van der Leij MJ, Bijzet J, Groen HJM, Kerstjens HAM, van der Wekken AJ, Kroesen BJ, Hiltermann TJN. Kievit H, et al. Among authors: van der wekken aj. Cancers (Basel). 2024 Jul 19;16(14):2592. doi: 10.3390/cancers16142592. Cancers (Basel). 2024. PMID: 39061230 Free PMC article.
76 results